Business
Notice of Annual General Meeting
Notice of Annual General Meeting.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8949Q\n Scancell Holdings Plc\n 01 November 2021\n \n \n \n 1 November 2021\n \n \n Scancell Holdings plc\n \n \n \n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n Notice of Annual General Meeting\n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that the Company's Annual General Meeting (\"AGM\") will take place on Tuesday, 23rd November 2021 at 14:00 GMT. \n \n \n \n \n \n A copy of the Notice has been uploaded to Scancell's website: \n \n www.scancell.co.uk/documents-presentations\n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n +44 (0) 20 3727 1000\n \n \n \n \n Dr John Chiplin, Executive Chairman\n \n \n \n \n \n \n \n Professor Lindy Durrant, CEO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)\n \n \n +44 (0) 20 7886 2500\n \n \n \n \n Freddy Crossley/Emma Earl (Corporate Finance)\n \n \n \n \n \n \n \n Rupert Dearden (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel Nicolaus Europe Limited (Joint Broker)\n \n \n +44 (0) 20 7710 7600\n \n \n \n \n Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)\n \n \n \n \n \n \n \n Nick Adams (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n FTI Consulting\n \n \n +44 (0) 20 3727 1000\n \n \n \n \n Simon Conway/Natalie Garland-Collins\n \n \n \n \n \n \n \n About Scancell\n \n \n Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications and development of a vaccine for COVID-19.\n \n \n \n \n \n ImmunoBody® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potenti...